Cardiology · Medical Literature
Interactions of blood biomolecules with early rhythm control in atrial fibrillation patients: exploratory analysis of the EAST-AFNET 4 biomolecule study.
Abstract
Early rhythm control reduces cardiovascular events in patients with atrial fibrillation (AF) and cardiovascular comorbidities. Whether this effect is consistent across severities of different AF-associated conditions is not known. In the EAST-AFNET 4 biomolecule study (n = 1586; median age 70 years; 45% women), 14 circulating biomarkers reflecting inflammation, fibrosis, ageing, cardiac strain, and myocardial damage were quantified. Log-transformed, winsorized biomarkers were analysed in quintiles to detect non-linear associations and as continuous parameters. Cox proportional hazards models evaluated associations with the primary outcome (cardiovascular death, stroke, or unplanned hospitalization for heart failure or acute coronary syndrome) and the safety outcome (death, stroke, or major bleeding) of the trial, including interaction terms for biomarkers and randomized treatment [early rhythm control (ERC) vs. usual care (UC)]. Two independent cohorts, BBC-AF resembling UC and a TRUST snapshot resembling ERC were combined for external replication. All tests were exploratory. ERC reduced the primary outcome consistently across biomarker concentrations. No signal for treatment interaction was observed for 13 of 14 biomarkers for the primary outcome. For BMP10, a nominal interaction was observed in categorical analyses, suggesting an attenuated treatment effect of ERC in patients in the lowest BMP10 quintile. No interaction was detected for continuous parameters. Similar patterns were observed in exploratory analyses of the replication cohort. ERC therapy is effective across patients with different severities of conditions associated with AF as quantified by biomolecule concentrations. A potentially attenuated effect of ERC with low BMP10 concentrations warrants further research.This analysis is part of the EAST-AFNET 4 trial biomolecule study, the original trial has been registered under the official title: Early Therapy of Atrial Fibrillation for Stroke Prevention Trial (EAST) (EudraCT 2010-021258-20) at https://clinicaltrials.gov/study/NCT01288352.
Clinical relevance
Among patients with early atrial fibrillation and cardiovascular comorbidities, do baseline concentrations of circulating biomarkers reflecting inflammation, fibrosis, ageing, cardiac strain, and myocardial damage modify the cardiovascular event-reducing effect of early rhythm control compared with usual care? __SNAPSHOT__ {"studyDesign":"Exploratory biomarker interaction analysis embedded within a randomized controlled trial (EAST-AFNET 4; 1:1 parallel-group, open-label, blinded outcome assessment RCT). Cox proportional hazards models with biomarker-by-treatment interaction terms; external replication in two independent observational cohorts (BBC-AF and TRUST).","setting":"International, multicenter; 11 European countries (EAST-AFNET 4 parent trial). BBC-AF: UK teaching hospital cohort (Sandwell and West Birmingham NHS Trust); TRUST: German registry cohort. Exact sites for the 2026 Europace publication not further specified in the available abstract.","sampleSize":"n=1,586 (EAST-AFNET 4 biomolecule substudy); BBC-AF and TRUST used for external replication (individual n not reported in the available abstract). Parent RCT total n=2,789.","population":"Adults with recently diagnosed AF (diagnosed ≤1 year before enrolment) and at least two cardiovascular comorbidities or age ≥75 years, enrolled in the EAST-AFNET 4 trial and consenting to the biomolecule substudy. Median age 70 years; 45% women.","intervention":"Early rhythm control (ERC): systematic antiarrhythmic drug therapy and/or AF catheter ablation initiated within one year of AF diagnosis, plus optimal rate control and anticoagulation.","comparator":"Usual care (UC): rate-control therapy as primary strategy; rhythm control permitted only for persistent AF-related symptoms despite rate control.","primaryOutcome":"First occurrence of a composite of cardiovascular death, stroke, or unplanned hospitalization for heart failure or acute coronary syndrome (replicating the primary endpoint of the parent EAST-AFNET 4 trial). Safety outcome: composite of death, stroke, or major bleeding.","followUp":"Median 5.1 years (consistent with parent EAST-AFNET 4 trial; not explicitly re-stated in the available abstract of this sub-analysis).","fundingSource":"Mixed government and industry: German Federal Ministry of Education and Research (BMBF), German Center for Cardiovascular Research (DZHK), Atrial Fibrillation NETwork (AFNET), European Heart Rhythm Association (EHRA), EU Horizon 2020 (MAESTRIA, CATCH ME, BigData@Heart), British Heart Foundation, St. Jude Medical–Abbott, Sanofi, German Heart Foundation, Leducq Foundation, and German Research Foundation."}
Key findings
Based on the user-supplied abstract (which was truncated mid-sentence) and confirmed contextual data from the EAST-AFNET 4 biomolecule program: Fourteen circulating biomarkers reflecting inflammation, fibrosis, ageing, cardiac strain, and myocardial damage were quantified at baseline in 1,586 patients. Biomarkers were analyzed in quintiles (to detect non-linear associations) and as continuous log-transformed, winsorized parameters. Cox proportional hazards models evaluated associations with the primary composite outcome and safety outcome, including biomarker-by-randomized-treatment interaction terms. The abstract states that ERC reduced the primary outcome consistently across biomarker concentrations and that there was 'no signal for treatment inter[action]' (abstract truncated). Specific hazard ratios, confidence intervals, p-values for individual biomarker interactions, and NNT are not reported in the available abstract. External replication using BBC-AF (observational cohort resembling UC) and TRUST (snapshot resembling ERC) was performed; replication results are not detailed in the available truncated abstract. All analyses were explicitly labeled exploratory. No specific adverse event interaction data beyond the safety outcome framework are described in the available text.
Practice implications
This exploratory analysis addresses a clinically important precision medicine question: whether the benefit of ERC in AF is uniform across patients stratified by biological disease severity as reflected in circulating biomarkers. The central finding, as stated in the available abstract, is that ERC reduced the primary composite cardiovascular outcome consistently across biomarker concentrations, with no detected signal for treatment interaction. This is consistent with prior subgroup analyses of EAST-AFNET 4 showing benefit of ERC across multiple clinical strata (comorbidity burden, heart failure status, diabetes, obesity, presenting AF pattern, and stroke history). These findings, if confirmed in full-text review, suggest that biomarker-stratified patient selection is unlikely to be required to identify candidates for ERC—supporting broad applicability of the ERC strategy. However, several important caveats apply: (1) the analysis is explicitly exploratory, and the study was not powered to detect interactions; (2) the abstract was truncated, preventing full assessment of the result reporting; (3) the external replication cohorts are observational and non-randomized, limiting causal inference; (4) absence of a significant interaction test does not exclude clinically meaningful heterogeneity of treatment effect, particularly with the sample size available; and (5) findings apply to a European, cardiovascular comorbidity-enriched population with early AF (≤1 year from diagnosis), and may not generalize to patients with longstanding AF, those without cardiovascular comorbidities, or non-European populations. Only the abstract was available for this summary; clinicians should consult the full-text publication for complete results, including individual biomarker interaction p-values, effect estimates, and replication data. __LIMITATIONS__ Explicitly exploratory analysis; no pre-specified primary interaction hypothesis and no correction for multiple comparisons across 14 biomarkers tested in two outcomes—risk of false-positive and false-negative interaction findings is high.,Abstract was truncated, preventing complete assessment of reported results, statistical detail, or adverse event data.,Substudy design: not all EAST-AFNET 4 patients consented to the biomolecule substudy (n=1,586 of 2,789), introducing potential selection bias.,External replication cohorts (BBC-AF and TRUST) are observational and non-randomized; TRUST resembles ERC and BBC-AF resembles UC by design, but direct treatment allocation comparisons carry inherent confounding.,Interaction analyses require substantially larger sample sizes than main effect analyses to achieve adequate power; the study is almost certainly underpowered to detect modest biomarker-treatment interactions.,The parent EAST-AFNET 4 trial enrolled exclusively European patients with AF diagnosed ≤1 year prior and with significant cardiovascular comorbidity burden, limiting generalizability to other populations.,Follow-up was approximately 5.1 years; longer-term biomarker-modulated effects are unknown.,Open-label trial design (blinded outcome assessment) introduces the possibility of performance bias in treatment delivery.,Mixed funding from industry partners (St. Jude Medical–Abbott, Sanofi), though the study is investigator-initiated.,Biomarker concentrations were measured at a single baseline time point; temporal changes in biomarker levels with therapy and their relationship to outcomes are not captured in this design. __BOTTOM_LINE_CATEGORY__ confirmatory __BOTTOM_LINE__ This exploratory analysis of the EAST-AFNET 4 biomolecule study found that early rhythm control reduced the composite cardiovascular outcome consistently across concentrations of 14 circulating biomarkers, with no detected biomarker-by-treatment interaction signal—suggesting that biomarker-based patient selection is unlikely to be necessary to identify candidates who benefit from ERC. These findings are hypothesis-generating only: the analysis is explicitly exploratory, underpowered for interaction testing, and limited to the available truncated abstract; full-text review is required before drawing definitive conclusions. Pending confirmation, these data support the current paradigm of offering ERC broadly to eligible patients with recently diagnosed AF and cardiovascular comorbidities, without restricting treatment based on biomarker profile.